^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Published date:
08/08/2023
Excerpt:
Tepotinib + osimertinib demonstrated durable responses and a manageable safety profile in patients with EGFRm METamp NSCLC following 1L osimertinib, especially in Asian patients. Tepotinib + osimertinib provides a potential chemotherapy-sparing oral targeted therapy option in this population with a high unmet need.
Source:
Title:
Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.
Published date:
05/25/2023
Excerpt:
...ORR was 51.6% (95% CI 33.1, 69.8), mDOR was 5.6 months (95% CI 2.9, ne), mPFS was 4.6 months (95% CI 2.7, 6.9)...In this interim analysis of INSIGHT 2, tepotinib + osimertinib was highly active with durable responses, and was well tolerated in pts with EGFRm NSCLC with METamp after progression on 1L osimertinib. Tepotinib + osimertinib provides a potential chemotherapy-sparing oral targeted therapy option in this population with a high unmet need.
DOI:
10.1200/JCO.2023.41.16_suppl.9021
Trial ID:
Source:
Title:
364P - Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Published date:
11/28/2022
Excerpt:
Twelve cases of patients with EGFR-mutant METamp NSCLC who received tepotinib plus an EGFR-TKI are presented….Nine patients received tepotinib plus osimertinib, two received tepotinib plus gefitinib, and one received both combinations sequentially....Per the treating physician’s assessment, 11 patients had clinical benefit, eight of whom were considered to have a partial response....The combination of tepotinib plus EGFR-TKIs showed promising clinical activity in patients with METamp NSCLC who have progressed on previous EGFR-TKIs, including those with several lines of prior treatment.
Source:
Title:
LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
Published date:
09/05/2022
Excerpt:
In this open-label 2-arm Phase II study, pts with advanced EGFRm NSCLC with METamp after progression on 1L osimertinib received tepotinib 500 mg (450 mg active moiety) + osimertinib 80 mg once daily (TEP+OSI)….Confirmed ORR was 54.5% in 22 FISH METamp TEP+OSI-treated pts with ≥9 months’ follow-up, with 6/12 responders still on treatment. In 48 FISH METamp pts with ≥3 months’ follow-up, ORR was 45.8% (with high rate of NE as BOR; Table)....In this initial analysis of INSIGHT 2, TEP+OSI was highly active and well tolerated in pts with EGFRm NSCLC with METamp after progression on 1L osimertinib and enables continuation of oral-only chemo-sparing therapy in this population with a high unmet need.
Trial ID:
Source:
Title:
EP08.02-162 - Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Published date:
07/12/2022
Excerpt:
Twelve cases of patients with EGFR-mutant METamp NSCLC, who received tepotinib plus an EGFR-TKI...Ten patients received tepotinib plus osimertinib, one patient received tepotinib plus gefitinib (who also received this combination in the INSIGHT study), and one patient received both combinations sequentially....Eleven patients had clinical benefit per the treating physician’s assessment, of whom eight were considered to have a partial response.
